RBC Capital Reiterates Outperform Rating on Mirum Pharmaceuticals, Inc. (MIRM)

Market Context

Mirum Pharmaceuticals, Inc. operates in the Healthcare sector. The stock currently trades at $128.31 with a market capitalization of $3.2B.

Analyst coverage from RBC Capital provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Mirum Pharmaceuticals, Inc..

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Mirum Pharmaceuticals, Inc.

Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Jul 07, 2026	RBC Capital	Outperform	N/A
Jul 02, 2026	JP Morgan	Overweight	N/A
Jun 15, 2026	Citizens	Market Outperform	N/A
Jun 11, 2026	Morgan Stanley	Overweight	N/A
Jun 02, 2026	Citigroup	Buy	N/A

Related Tools: Analyst Ratings Dashboard | View MIRM Stock Page